Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
R&D The SPC waiver: How do we restore the intended balance betwe... Biosimilars promote cost-effective solutions to critical healthcare challenges.
Views & Analysis Huge scale of Brexit threat to Europe’s medicines supplies r... New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.